Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy

This study has been completed.
Information provided by (Responsible Party):
Dr. Lawrence Hookey, Queen's University Identifier:
First received: April 20, 2009
Last updated: August 27, 2015
Last verified: August 2015
Pico-Salax is an osmotic and stimulant bowel cleansing agent used prior to colonoscopy. It is unknown whether splitting the doses (i.e. taking the second dose the morning of the colonoscopy) results in a better bowel cleansing, as research with other agents suggests this may be the case. This study aims to assess whether splitting the dose of Pico-Salax results in a better bowel cleansing than traditional dosing.

Condition Intervention Phase
Drug: Pico-Salax
Drug: Split Dose Pico-Salax
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy.

Resource links provided by NLM:

Further study details as provided by Dr. Lawrence Hookey, Queen's University:

Primary Outcome Measures:
  • bowel cleansing assessed by the Ottawa Bowel Preparation Scale [ Time Frame: day of colonoscopy ]

Secondary Outcome Measures:
  • patient tolerance of preparation [ Time Frame: day of colonoscopy ]

Enrollment: 250
Study Start Date: November 2008
Study Completion Date: August 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Split Dose
Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
Drug: Split Dose Pico-Salax
One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
Active Comparator: Traditional Dose
Both doses of Pico-Salax taken the evening prior to colonoscopy.
Drug: Pico-Salax
Both doses of Pico-Salax taken the evening prior to colonoscopy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • colonoscopy indicated

Exclusion Criteria:

  • congestive heart failure
  • ascites
  • renal failure
  • hyponatremia
  • previous intestinal surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00885274

Canada, Ontario
Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2
Sponsors and Collaborators
Queen's University
Principal Investigator: Lawrence Hookey, MD Queen's University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Lawrence Hookey, Assistant professor of Medicine, Queen's University Identifier: NCT00885274     History of Changes
Other Study ID Numbers: Hookey Pico-Salax Timing
Study First Received: April 20, 2009
Last Updated: August 27, 2015

Additional relevant MeSH terms:
Magnesium Oxide
Citric Acid
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents
Calcium Chelating Agents
Chelating Agents
Sequestering Agents processed this record on May 25, 2017